Aperio Group’s Adaptimmune Therapeutics ADAP Stock Holding History

Aperio Group’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$149K	Sell	27,556 -6,346	-19%	-$34.5K	﹤0.01%	2353
2020 Q3	$271K	Buy	33,902 +10,575	+45%	+$92.5K	﹤0.01%	2110
2020 Q2	$234K	Buy	23,327 +4,729	+25%	+$29.7K	﹤0.01%	2130
2020 Q1	$51K	Buy	+18,598	New	+$61.7K	﹤0.01%	2277
2019 Q4	–	Sell	-19,581	Closed	-$30K	–	2325
2019 Q3	$30K	Sell	19,581 -2,411	-11%	-$5.63K	﹤0.01%	2294
2019 Q2	$88K	Buy	+21,992	New	+$89.7K	﹤0.01%	2416
2018 Q4	–	Sell	-10,789	Closed	-$146K	–	2289
2018 Q3	$146K	Buy	+10,789	New	+$113K	﹤0.01%	2224

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Aperio Group's ADAP Position: Q4 2020 in Review

Aperio Group reduced its Adaptimmune Therapeutics (ADAP) stake by 19% in Q4 2020, selling an estimated $34.5K and leaving 27,556 shares worth $149K. The position accounts for ﹤0.01% of the portfolio, ranked #2353.

Aperio Group first reported a position in ADAP in Q3 2018 and has held it in 7 quarters since. The position peaked at $271K in Q3 2020. 87 funds tracked by Wall St. Rank hold ADAP as of Q4 2020.

Aperio Group held 27,556 shares of Adaptimmune Therapeutics worth $149K as of Q4 2020.
Aperio Group sold 6,346 Adaptimmune Therapeutics shares in Q4 2020, an estimated $34.5K.
Adaptimmune Therapeutics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2353 holding.
Aperio Group first reported a position in Adaptimmune Therapeutics in Q3 2018 and has held it in 7 quarters since.
Aperio Group's Adaptimmune Therapeutics position peaked at $271K in Q3 2020.
87 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.